{"id":20726,"date":"2025-05-26T08:08:43","date_gmt":"2025-05-26T06:08:43","guid":{"rendered":"https:\/\/kymos.com\/?page_id=20726"},"modified":"2026-03-19T12:35:21","modified_gmt":"2026-03-19T11:35:21","slug":"innovacio-2","status":"publish","type":"page","link":"https:\/\/kymos.com\/ca\/innovacio-2\/","title":{"rendered":"Innovaci\u00f3"},"content":{"rendered":"

Innovation<\/h1><\/div>

Innovation is at the heart of everything we do, constantly driving us to explore new possibilities, improve processes, and create solutions that shape the future.<\/p>\n<\/div><\/div><\/div><\/div><\/div>

Driving Breakthroughs<\/p>\n<\/div>

<\/div><\/div>

Pioneering Innovation in Pharma & Biotech R&D<\/h2><\/div>

Research and development are essential to all industries but even more so in the pharma and biotech sectors where the rapid flow of new innovations compels players across the value chain to rise to the challenge.<\/strong> Kymos was founded by expert researchers and as a CRO we remain committed to constantly upgrading to the latest cutting-edge technology for analytical development,<\/strong> characterization, and quality control of drugs. In fact, we have mastered disruptive, emerging technologies long before our competitors: our 10-year-old biologics laboratories, our work with topical generics or our research in new advanced therapies. Some of our R&D projects have excelled, obtaining public grants and financial aid.<\/p>\n<\/div>

<\/div><\/div><\/div><\/div><\/div><\/div>
<\/span><\/div>

Multilocalization project south korea office<\/h4><\/div>

Granting resolution of January 10, 2024 under EMT\/2528\/2023, of July 10, by which the call for the line of subsidies for multi-location projects for the year 2023 is opened grants Kymos SL the corresponding aid for the company to establish a Representative Office in South Korea, located in the city of Seoul.<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div>

\"innovative<\/span><\/div>

Innovative sme seal<\/h4><\/div>

KYMOS SPAIN has renewed the INNOVATIVE SME SEAL awarded by the Ministry of Science, Innovation, and Universities of the Government of Spain and is registered in the Registry of INNOVATIVE SMEs.<\/p>\n

This seal is a distinction that recognizes our activities in the field of Research, Development, and Innovation (R&D&I) within our business operations.<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div>

<\/span><\/div>

Advanced therapy medicinal products (atmps)<\/h4><\/div>

DEVELOPMENT OF THE FIRST TECHNOLOGICAL PLATFORM FOR ANALYTICAL ASSAYS IN GENE THERAPY. This project is also financed through a grant TORRES QUEVEDO for contracts No. PTQ2021-012177 dated November 1st, 2022.<\/p>\n

The objective of the project is to develop a test platform for the characterization and definition of the quality attributes of gene therapy drugs.<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div>

<\/span><\/div>

ADVANCED THERAPY MEDICINAL PRODUCTS (ATMPs)<\/h4><\/div>

STUDY AND DEVELOPMENT OF THE FIRST TECHNOLOGICAL PLATFORM FOR ASSAYS FOR ADENO ASSOCIATED VIRUSES IN GENE THERAPY. Joint call by the CARLOS III HEALTH INSTITUTE (ISCIII) and the CENTER FOR TECHNOLOGICAL AND INDUSTRIAL DEVELOPMENT (CDTI), included in the Strategic Project for Economic Recovery and Transformation for Health of Vanguard, within the framework of the Recovery, Transformation and Resilience plan and sponsored with NextGenerationEU funds. CDTI project assigned to Kymos: IDI-20230061 dated January 27th, 2023. Collaboration project between the VIRAL VECTOR PRODUCTION UNIT (a mixed platform of the Autonomous University of Barcelona and the Vall d\u2019Hebron Research Institute) and KYMOS S.L.<\/p>\n

The objective of the project is to study and develop the first technological test platform for the characterization and definition of the quality attributes of gene therapy drugs, specifically adeno-associated viruses (AAV), and to offer to the market a complete characterization and quality control service in a regulated and validated environment that allows reducing the development time of new gene therapy drugs.<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div>

<\/span><\/a><\/span>
<\/span><\/div>

Marche Biobank Project<\/h4><\/div>

PERSONALIZED MEDICINES: DRUGS, DIAGNOSTICS AND NEW THERAPEUTIC APPROACHES Establishment of A.T.S. (Scope Temporary Association) and special collective mandate with representation for POR MARCHE FESR 2014\/2020 \u2013 ASSE 1 \u2013 OS 2 \u2013 AZIONE 2.1 Support for the Development of Technological Platforms for Collaborative Research, Development and Innovation in the areas of Intelligent Specialization.<\/p>\n<\/div>

www.linkedin.com\/company\/marchebiobank<\/a>
\nwww.marchebiobank.it\/en\/homepage<\/a>
\nMarche Biobank poster<\/a><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div>

<\/span><\/div>

Development of a diagnostic test based on miRNA-574-5p as a predictive biomarker for prostaglandin E2-mediated tumors<\/h4><\/div>

Using a previously standardized and GLP validated analytical method for the quantification of miRNAs from plasma, we will conduct an explorative biomarker study to determine miRNA-574-5p as a non-small cell lung cancer (NSCLC) stratification marker. With miRNA-574-5p as a biomarker, we hope to establish a threshold value in blood from which a PGE2-dependent lung cancer can be predicted, and thus also the therapeutic outcome with PGE2 inhibitors.<\/p>\n

A research project in cooperation with Technical University Darmstadt and University of Gie\u00dfen since 2019; funded by KMU-innovativ of the Federal Ministry of Education and Research (BMBF).<\/p>\n

See our publications:
\nFASEB BioAdvances: Validation of extracellular miRNA quantification in blood samples using RT-qPCR
\nBIOspectrum: Fl\u00fcssigbiopsie: Standardisierte mikroRNA-Analytik \u2013 die gro\u00dfe Chance f\u00fcr Biomarkerstudien?<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div>

<\/span><\/div>

Determination of micro RNAs and RNA therapeutics in human serum and plasma under Good Laboratory Practice (GLP) conditions<\/h4><\/div>

Validation of the method for miRNA isolation from plasma and quantification by quantitative PCR under Good Laboratory Practice (GLP) is the basis for a standardised analysis procedure of miRNAs to provide reproducible determination of miRNA biomarkers.<\/p>\n

A research project in cooperation with Technical University Darmstadt since 2017; funded by ZIM of the Federal Ministry of Education and Research (BMBF).<\/p>\n

Find our more about our Nucleic Acids Services<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div>

OligoXplorer: the first platform for the analysis of therapeutic oligonucleotides in the Marche Region<\/h4><\/div>

The OligoXplorer project goal is to develop the first platform in the Marche Region for the analysis of therapeutic oligonucleotides such as antisense oligonucleotides (ASO) and RNA molecules like small interfering RNA (siRNA) and micro-RNA (miRNA). This platform will address the complexity of characterizing these molecules, which requires various analytical techniques because of their structural diversity and chemical modifications.<\/p>\n

This will be an innovative initiative in the Marche Region and will act as the first option provider for local pharmaceutical companies and research labs. By offering this service, OligoXplorer will support the development of nucleic acid-based therapies in Italy, and will ensure drug safety and quality while promoting the regional innovation.<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div>

<\/span><\/div>

Biosimilars<\/h4><\/div>

IMPLEMENTATION OF NEW ANALYTICAL METHODS FOR BIOSIMILARS. Decision of the CENTRO PARA EL DESARROLLO TECNOL\u00d3GICO E INDUSTRIAL (CDTI) for a financial aid to the development of the Project IDI-20140009 dated February 3, 2014.<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div>

<\/span><\/div>

Glycosaminoglycans<\/h4><\/div>

DEVELOPMENT OF A NEW ANALYTICAL PLATFORM FOR THERAPEUTIC GLYCOSAMINOGLYCANS. Decision EMO\/1430\/2015, dated June 25, 2015 (DOGC n\u00fam. 6902 de 30\/06\/2015) regarding the call for NUCLEUS OF INDUSTRIAL RESEARCH AND EXPERIMENTAL DEVELOPMENT (file number RD15-1-0080). This project has received funding from the European Union through the European Regional Development Fund (ERDF). With the collaboration from ACCIO.<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div>

<\/span><\/div>

Medical Device<\/h4><\/div>

Resolution EMC\/1845\/2016 dated 11th of July (DOGC number 7172 de 28.7.2106) regarding the call for aids in NUCLEUS OF INDUSTRIAL RESEARCH AND EXPERIMENTAL DEVELOPMENT registered with the expedient number RD16-1-0030 to grant the project BIODEGRADABLE MEDICAL DEVICE AS A TOOL FOR THERAPEUTIC IMPROVEMENT IN A LONG-TERM ILLNESS. This project has received funding from the European Union through the European Regional Development Fund (ERDF). With the collaboration from ACCIO.<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div>

<\/span><\/div>

Industrial PhD<\/h4><\/div>

Third final partial resolution of the INDUSTRIAL PHD 2017 CALL of the Ag\u00e8ncia de Gesti\u00f3 d\u2019Ajuts Universitaris i de Recerca (AGAUR) of the Departament d\u2019Empresa i Coneixement de la Generalitat de Catalunya dated 24th of November, 2017. Expedient number 2017 DI 045 on behalf of the company Kymos Pharma Services, S.L. and of the research organization Universitat Aut\u00f2noma de Barcelona.<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div>

<\/span><\/div>

High Impact<\/h4><\/div>

Resolution of the Ag\u00e8ncia per a la Competitivitat de l\u2019Empresa, ACCI\u00d3, dated 18th of October 2017, in accordance with the Resolution EMC\/1900\/2017 approving the regulatory basis of the program of aids to high impact investments, and the Resolution EMC\/2169\/2017 openning the 2017 call, registered with the reference file number ACIAI17-1-0052: CREATION OF NEW JOBS IN THE PHARMACEUTICAL AND BIOTECHNOLOGICAL SECTOR (KREALAB).<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>

<\/div><\/div><\/div><\/div>

Descobreix m\u00e9s sobre Kymos<\/h2><\/div>
Sobre nosaltres<\/span><\/i><\/a><\/div><\/div><\/div><\/div><\/div>\n
<\/div><\/div><\/div><\/div>

Poseu-vos en contacte amb nosaltres<\/p>\n<\/div>

<\/div><\/div>

Troba una ubicaci\u00f3 a prop teu<\/h2><\/div><\/div><\/div><\/div><\/div>\n
<\/span><\/div><\/div><\/div>

SPAIN SITE<\/span><\/strong>
\nRonda Can Fatj\u00f3 7B
\n08290 Cerdanyola del Vall\u00e8s
\nBarcelona, Spain
\nVAT n\u00ba ES-B62170337<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div>

ITALY SITE<\/span><\/strong>
\nVia Emilia-Romagna, 28-30-32
\n60030 Monsano
\nAncona, Italy P.
\nIVA 01564160420<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div>

GERMANY SITE<\/span><\/strong>
\nWeism\u00fcllerstra\u1e9ee 45
\nD-60314 Frankfurt\/Main
\nGermany USt-IdNr:
\nDE 226546121<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div>

DENMARK SITE<\/span><\/strong>
\nAgern All\u00e9 3
\nDK 2970 H\u00f8rsholm
\nDenmark
\nCVR: 25194934
\n<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div>

SOUTH KOREA OFFICE<\/span><\/strong>
\n37F ASEM Tower, 517 Yeongdong-Daero 06164 Gangnam-gu, Seoul, Korea<\/span>
\nVAT n\u00ba 839-88-03795<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div>

HEADQUARTERS<\/span><\/strong>
\nRonda Can Fatj\u00f3 5D
\n08290 Cerdanyola del Vall\u00e8s
\nBarcelona, Spain
\nVAT n\u00ba ES-B70843693 <\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div>

Contact<\/span><\/i><\/a><\/div><\/div><\/div><\/div><\/div>\n<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":12,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"100-width.php","meta":{"_acf_changed":false,"footnotes":""},"categories":[],"tags":[],"class_list":["post-20726","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nRecerca i desenvolupament a Kymos<\/title>\n<meta name=\"description\" content=\"Recerca i desenvolupament a Kymos a CRO per a serveis bioanal\u00edtics i CMC per a petites mol\u00e8cules, productes biol\u00f2gics i \u00e0cids nucleics.\" \/>\n<meta name=\"robots\" content=\"noindex, follow\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Recerca i desenvolupament a Kymos\" \/>\n<meta property=\"og:description\" content=\"Recerca i desenvolupament a Kymos a CRO per a serveis bioanal\u00edtics i CMC per a petites mol\u00e8cules, productes biol\u00f2gics i \u00e0cids nucleics.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kymos.com\/ca\/innovacio-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Kymos\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-19T11:35:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kymos.com\/wp-content\/uploads\/2023\/06\/Foto-Logo-Kymos-Edificio.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"1200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@KymosGroup\" \/>\n<meta name=\"twitter:label1\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"14 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/innovacio-2\\\/\",\"url\":\"https:\\\/\\\/kymos.com\\\/ca\\\/innovacio-2\\\/\",\"name\":\"Recerca i desenvolupament a Kymos\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/#website\"},\"datePublished\":\"2025-05-26T06:08:43+00:00\",\"dateModified\":\"2026-03-19T11:35:21+00:00\",\"description\":\"Recerca i desenvolupament a Kymos a CRO per a serveis bioanal\u00edtics i CMC per a petites mol\u00e8cules, productes biol\u00f2gics i \u00e0cids nucleics.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/innovacio-2\\\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/kymos.com\\\/ca\\\/innovacio-2\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/innovacio-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/kymos.com\\\/ca\\\/inici\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innovaci\u00f3\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/kymos.com\\\/ca\\\/#website\",\"url\":\"https:\\\/\\\/kymos.com\\\/ca\\\/\",\"name\":\"Kymos Group\",\"description\":\"Kymos Group\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/kymos.com\\\/ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ca\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Recerca i desenvolupament a Kymos","description":"Recerca i desenvolupament a Kymos a CRO per a serveis bioanal\u00edtics i CMC per a petites mol\u00e8cules, productes biol\u00f2gics i \u00e0cids nucleics.","robots":{"index":"noindex","follow":"follow"},"og_locale":"ca_ES","og_type":"article","og_title":"Recerca i desenvolupament a Kymos","og_description":"Recerca i desenvolupament a Kymos a CRO per a serveis bioanal\u00edtics i CMC per a petites mol\u00e8cules, productes biol\u00f2gics i \u00e0cids nucleics.","og_url":"https:\/\/kymos.com\/ca\/innovacio-2\/","og_site_name":"Kymos","article_modified_time":"2026-03-19T11:35:21+00:00","og_image":[{"width":1200,"height":1200,"url":"https:\/\/kymos.com\/wp-content\/uploads\/2023\/06\/Foto-Logo-Kymos-Edificio.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@KymosGroup","twitter_misc":{"Temps estimat de lectura":"14 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/kymos.com\/ca\/innovacio-2\/","url":"https:\/\/kymos.com\/ca\/innovacio-2\/","name":"Recerca i desenvolupament a Kymos","isPartOf":{"@id":"https:\/\/kymos.com\/ca\/#website"},"datePublished":"2025-05-26T06:08:43+00:00","dateModified":"2026-03-19T11:35:21+00:00","description":"Recerca i desenvolupament a Kymos a CRO per a serveis bioanal\u00edtics i CMC per a petites mol\u00e8cules, productes biol\u00f2gics i \u00e0cids nucleics.","breadcrumb":{"@id":"https:\/\/kymos.com\/ca\/innovacio-2\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kymos.com\/ca\/innovacio-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/kymos.com\/ca\/innovacio-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kymos.com\/ca\/inici\/"},{"@type":"ListItem","position":2,"name":"Innovaci\u00f3"}]},{"@type":"WebSite","@id":"https:\/\/kymos.com\/ca\/#website","url":"https:\/\/kymos.com\/ca\/","name":"Kymos Group","description":"Kymos Group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kymos.com\/ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"}]}},"_links":{"self":[{"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/pages\/20726","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/comments?post=20726"}],"version-history":[{"count":2,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/pages\/20726\/revisions"}],"predecessor-version":[{"id":35781,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/pages\/20726\/revisions\/35781"}],"wp:attachment":[{"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/media?parent=20726"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/categories?post=20726"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kymos.com\/ca\/wp-json\/wp\/v2\/tags?post=20726"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}